Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enobosarm in postmenopausal women with stress urinary incontinence
NCT03241342Phase 2Completed
- Sponsor
- GTx
- Start
- Aug 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of enobosarm in stress urinary incontinence (SUI) (3 arms), sponsored by GTx. Primary endpoint: Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at 12 weeks. Started Aug 2017; status: completed.
02
Drugs
enobosarm
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on NCT03241342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241342.